Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BDA MDI HFO 160/180 μg · 1 trial · 1 indication
To assess the equivalence of BDA MDI HFO relative to BDA MDI HFA on lung function in participants with asthma.
| Arm | Type | Description |
|---|---|---|
| BDA MDI HFO | ACTIVE_COMPARATOR | 160/180 µg Budesonide/albuterol pressurized inhalation suspension, HFO |
| BDA MDI HFA | ACTIVE_COMPARATOR | 160/180 µg Budesonide/albuterol pressurized inhalation suspension, HFA |
| Placebo MDI HFA | PLACEBO_COMPARATOR | Placebo pressurized inhalation suspension, HFA |
| Name | Type | Description |
|---|---|---|
| BDA MDI HFO 160/180 μg | DRUG | Budesonide/albuterol pressurized inhalation suspension, HFO |
| BDA MDI HFA 160/180 μg | DRUG | Budesonide/albuterol pressurized inhalation suspension, HFA |
| Placebo MDI HFA | DRUG | Placebo pressurized inhalation suspension, HFA |
Inclusion Criteria: * Participant must be ≥ 18 years of age at the time of signing the ICF. * Participants who have physician diagnosed asthma as defined by GINA for at least 12 months prior to Visit 1. * Eligible participants are on either a) no daily inhaled maintenance therapy or b) daily inhale...
Top 16 of 18 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 5 | PHASE3 | QVM149, QMF149, Glycopyrronium bromide |
| GSK plc Sponsored ADR | GSK | 10 | PHASE3 | Trelegy Ellipta, Depemokimab, HFA-152a, GSK5784283, Ventolin |
| Teva Pharmaceutical Industries Limited Sponsored ADR | TEVA | 4 | PHASE3 | TEV-56248, ProAir (albuterol sulfate eMDPI), Budesonide/Formoterol SPIROMAX, Reslizumab |
| Sanofi SA Sponsored ADR | SNY | 8 | PHASE3 | Dupilumab, Lunsekimig |
| AstraZeneca PLC | AZN | 28 | PHASE3 | Benralizumab, Tezepelumab, Budesonide/formoterol, Albuterol/budesonide, PT007 |
| Pfizer Inc. | PFE | 4 | PHASE3 | Tilrekimig, PF-07275315, PF-08103402 |
| Generate Biomedicines, Inc. | GENB | 3 | PHASE3 | GB-0895 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Brenipatide |
| Incyte Corporation | INCY | 1 | PHASE2 | povorcitinib |
| Upstream Bio, Inc. | UPB | 1 | PHASE2 | Verekitug |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1 | PHASE2 | ARO-RAGE |
| Amgen Inc. | AMGN | 1 | PHASE1 | AMG 691 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Apogee Therapeutics, Inc. | APGE | 1 | PHASE1 | APG777 |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE1 | CDX-622 |
BDA MDI HFO 160/180 μg is an investigational inhaled asthma therapy developed by AstraZeneca PLC. It is a small molecule delivered by metered dose inhaler (MDI) using HFO, a next generation propellant, at 160/180 μg. It is being studied as a potential alternative to an approved asthma treatment that uses HFA propellant.
BDA MDI HFO 160/180 μg is being developed for the treatment of asthma. Its Phase 3 trial enrolled adults with asthma to assess lung function compared with an approved asthma treatment formulated with HFA propellant. The drug remains investigational and is not established as a marketed therapy.
AstraZeneca PLC (ticker AZN) is the developer of BDA MDI HFO 160/180 μg. The company is running the clinical program for this next generation propellant formulation in asthma.
BDA MDI HFO 160/180 μg is in Phase 3 development for asthma. One Phase 3 trial has been completed, and no trials are currently listed as active. The drug is investigational and has not been approved by the FDA.
BDA MDI HFO 160/180 μg has been studied in Phase 3 trial NCT06502366, titled a study to investigate the effect on lung function of BDA formulated with a next generation propellant compared with an approved asthma treatment (BDA with HFA propellant) in participants with asthma. The trial is completed and enrolled 424 participants.
The Phase 3 trial NCT06502366 was a randomized, double-blind, placebo-controlled study in 424 adults with asthma, aged 18 years and older, across the United States, China, Malaysia, Mexico, Thailand, and Vietnam. It compared BDA formulated with a next generation propellant against an approved asthma treatment using HFA propellant.